Market Overview for Perceiva
MacuSight is advancing Perceiva as a potential therapeutic for the treatment of a number of major ocular disease indications including diabetic macular edema (DME), wet age-related macular degeneration (wet AMD), uveitis and dry age-related macular degeneration (dry AMD). Additionally, the company is using Perceiva to evaluate the potential role for sirolimus in the treatment of dry eye syndrome (DES).
- DIABETIC MACULAR EDEMA
- Leading cause of vision loss among working-age adults
- Affects 1-2 million Americans
- Estimated 10% annual market growth due to diabetic epidemic
- Sirolimus inhibits HIF-1 mediated hypoxic response
- WET AMD
- Leading cause of vision loss among aging adults
- Affects ~2 million Americans
- Estimated 6% annual market growth due to aging population
- Sirolimus inhibits proliferation, angiogenesis and fibrosis
- DRY EYE SYNDROME
- Most prevalent form of ocular discomfort and irritation
- Affects ~20 million Americans
- Highly underserved market
- Sirolimus inhibits the inflammation that reduces natural tear production
- UVEITIS
- Responsible for ~10% of visual handicaps in Western world
- Affects > 2 million Americans
- Significant un-met need for local, minimally-invasive treatment
- Sirolimus inhibits T-cells and multiple pro-inflammatory factors
- DRY AMD
- Most common form of AMD
- Affects > 10 million Americans
- Prevalence will double over next decade
- Sirolimus inhibits inflammation which plays a role in disease initiation and progression
|
